Article

VIDEO: Richard Stefanacci, DO, Addresses Cost Concerns of Neurodegenerative Diseases

Conference|NAMCP: National Association of Managed Care Physicians Forum

Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases.

Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases. One is the actual cost of the disease and the second is the cost of diagnostic testing. Dr Stefanacci also says that treatments are now currently inexpensive, but with new emerging therapiess the costs will rise.

This video was taken on Thursday, November 8 at the NAMCP Fall Forum in Las Vegas, NV.

Related Videos
Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC
Dr Peter Schmid
Dr Sheela Rao
Davey Daniel, MD.
Meredith McKean, MD, MPH, board-certified medical oncologist and director of Melanoma and Skin Cancer Research for Sarah Cannon Research Institute at Tennessee Oncology
ERS 2024 Recap
Matthew Zachary, founder of Stupid Cancer.
Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel
Related Content
AI robot thinking | Image credit: phonlamaiphoto – stock.adobe.com
September 17th 2024

Are AI-Powered Robots the Future of Respiratory Health Care?

Hayden E. Klein
Introducing artificial intelligence (AI)–powered robots like AMECA into health care comes with potential benefits like improved clinical decision-making and faster diagnoses, but also presents challenges such as misinformation risks and data privacy concerns.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Rising Incidence of Young-Onset Cancer: Exploring the Causes and Generational Risk Factors
September 16th 2024

Rising Incidence of Young-Onset Cancer: Causes and Generational Risk Factors

Alana Hippensteele
At ESMO Congress 2024, Shuji Ogino, MD, PhD, MS, explained that the rising incidence of young-onset cancer may be due to generational risk factors such as lifestyle, diet, and environmental changes, emphasizing the need for long-term research and follow up to understand early-life influences on cancer development.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials
September 15th 2024

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

Alana Hippensteele
Clinical research presented at the European Society for Medical Oncology Congress 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers, such as circulating tumor DNA and KRAS mutations, in guiding treatment decisions.
Dr Angeles Alvarez Secord on "Exciting" Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer
September 15th 2024

Dr Angeles Alvarez Secord on "Exciting" Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer

Rose McNulty
Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian cancer, which is a challenging patient population to treat, Angeles Alvarez Secord, MD, MHSc, gynecologic oncologist at Duke Health, said.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo